SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2977So much to look at this morning! ash.confex.com <i>due primarily to fiscaram(o)uche-11/7/2013
2976>> the coolness factor of the trial just went way up << It was actuscaram(o)uche-11/5/2013
2975>> can't find the peptide vaccine mentioned at PubMed << All I scaram(o)uche-11/5/2013
2974More of the same...... thestreet.comscaram(o)uche-11/5/2013
2973fwiw...... Blood. 2013 Oct 30. [Epub ahead of print] Three-year efficacy, safescaram(o)uche-11/4/2013
2972This from twitter's Andy Biotech..... went through slides from quarterlscaram(o)uche-10/31/2013
2971someone at ct.gov is a tease...... LGX818 trial launches, according to yesterdascaram(o)uche-10/30/2013
2970INC280 going it alone in a second HCC trial, this time a placebo controlled phasscaram(o)uche-10/29/2013
2969Any pcyc freaks (wealthy $%#^&s!) want to bring us up to speed on pan-deacetscaram(o)uche110/28/2013
2968So, relative to an earlier phase II trial using panobinostat, dose is reduced (scaram(o)uche-10/28/2013
2967Clin Cancer Res. 2013 Oct 23. [Epub ahead of print] JAK1/2 and Pan-Deacetylase scaram(o)uche-10/28/2013
2966Hadn't seen the edit, last revisions (9/26)..... "Escalating doses of scaram(o)uche-10/28/2013
2965The way things are looking, makes one wonder if, using a combo of VX-509 and anyscaram(o)uche-10/28/2013
2964Recall that tofacitinib, the PFE Jak compound approved for second line RA, had sBiotech Jim-10/28/2013
2963This is interesting: >>In cellular knock-down experiments with siRNA we cBiomaven-10/27/2013
2962Cool molecule (btk and jak3), but what off-target activities will also be observscaram(o)uche-10/27/2013
2961>> certainly complicates the development plan << There is an interescaram(o)uche-10/26/2013
2960Timely..... projected enrollment 420, projected completion is 6/16, looks liscaram(o)uche-10/25/2013
2959There's this from this year's AACR, re. the second inhibitor from NewLinscaram(o)uche-10/24/2013
2958(Haven't a clue, Sales. But thanks for the note, and love BJ's thoughtsscaram(o)uche-10/24/2013
2957BTW, I have a copy of the mentioned PhD thesis if one wants to send me a PM to gBiotech Jim-10/23/2013
2956<"And our recently acquired JAK 1, 2 inhibitor Momelotinib has been succBiotech Jim-10/23/2013
2955Rick, "does anyone know when GILD plans to launch its phase III program wisoftware salesperson-10/23/2013
2954Your thoughts here were so insightful that I couldn't find them, due to firsscaram(o)uche-10/20/2013
2953But I can find the vaccine at CT.gov........ clinicaltrials.gov That's onescaram(o)uche-10/17/2013
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News